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CONDENSATION 
 
Combination of maternal factors and fetal biometry predict 90% of small for gestational age 
neonates born within two weeks of assessment at screen-positive-rate of 23%. 
 
 
AT A GLANCE 
 
A. To investigate the potential value of maternal characteristics and medical history, 
sonographically estimated fetal weight (EFW) and biomarkers of impaired placentation at 
35+0 - 36+6 weeks’ gestation in the prediction of delivery of small for gestational age (SGA) 
neonates. 
 
B. Prediction of 90% of SGA neonates delivering within two weeks of assessment was 
achieved by a screen positive rate of 67% in screening by maternal factors, 23% by 
maternal factors and EFW and 21% by the addition of biomarkers; the respective values for 
prediction of SGA neonates delivering at any stage after assessment were 66%, 32% and 
30%. 
  
C. Addition of biomarkers of impaired placentation only marginally improves the predictive 
performance of small for SGA neonates, achieved by maternal factors and fetal biometry at 
35+0 – 36+6 weeks’ gestation.  
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ABSTRACT 
 
Background: Small for gestational age (SGA) neonates are at increased risk of perinatal mortality 
and morbidity, but the risks can be substantially reduced if the condition is identified prenatally, 
because in such cases close monitoring and appropriate timing of delivery and prompt neonatal 
care can be undertaken. The traditional approach of identifying pregnancies with SGA fetuses is 
maternal abdominal palpation and serial measurements of symphysial-fundal height, but the 
detection rate of this approach is less than 30%. A higher performance of  screening for SGA is 
achieved by sonographic fetal biometry during the third trimester; screening at 30-34 weeks’ 
gestation identifies about 80% of SGA neonates delivering preterm but only 50% of those 
delivering at term, at screen positive rate of 10%. There is some evidence that routine ultrasound 
examination at 36 weeks' gestation is more effective than that at 32 weeks in predicting birth of 
SGA neonates. 
 
Objective: To investigate the potential value of maternal characteristics and medical history, 
sonographycally estimated fetal weight (EFW) and biomarkers of impaired placentation at 35+0 - 
36+6 weeks’ gestation in the prediction of delivery of small for gestational age (SGA) neonates. 
 
Methods: A dataset of 124,443 prospectively examined singleton pregnancies at 11+0 - 13+6 weeks’ 
gestation was used to derive, through multivariable logistic regression analysis, the patient-
specific prior risk for delivery of SGA neonate with birthweight <10th percentile for gestational age 
from maternal characteristics and medical history. A dataset of 19,209 singleton pregnancies 
undergoing screening at 35+0 - 36+6 weeks’ gestation was divided into a training set and a 
validation set. The training dataset was used to develop models from multivariable logistic 
regression analysis to determine whether addition of uterine artery pulsatility index (UtA-PI), 
umbilical artery PI (UA-PI), fetal middle cerebral artery PI (MCA-PI), maternal serum placental 
growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFLT) improved the performance of 
maternal factors and EFW in the prediction of delivery of SGA neonates. The models were then 
tested in the validation dataset to assess performance of screening. 
 
Results In the training dataset, in the SGA group, compared to those with birthweight ≥10th 
percentile, the median multiple of the median (MoM) values of PLGF and MCA-PI were reduced, 
whereas UtA-PI, UA-PI and sFLT were increased. Multivariable regression analysis demonstrated 
that in the prediction of SGA <10th there were significant contributions from maternal factors, EFW 
Z-score, UtA-PI MoM, MCA-PI MoM and PlGF MoM. In the validation dataset, prediction of 90% 
of SGA neonates delivering within two weeks of assessment was achieved by a screen positive 
rate of 67% in screening by maternal factors, 23% by maternal factors and EFW and 21% by the 
addition of biomarkers; the respective values for prediction of SGA neonates delivering at any 
stage after assessment were 66%, 32% and 30%. 
 
Conclusion: Addition of biomarkers of impaired placentation only marginally improves the 
predictive performance for delivery of SGA neonates achieved by maternal factors and fetal 
biometry at 35+0 - 36+6 weeks’ gestation. 
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INTRODUCTION 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
Small for gestational age (SGA) neonates are at increased risk of perinatal mortality and morbidity, 
but the risks can be substantially reduced if the condition is identified prenatally, because in such 
cases close monitoring and appropriate timing of delivery and prompt neonatal care can be 
undertaken.1,2 The traditional approach of identifying pregnancies with SGA fetuses is maternal 
abdominal palpation and serial measurements of symphysial-fundal height, but the detection rate 
(DR) of this approach is less than 30%.3,4 A few studies involving a small number of cases (725-
3,690) reported that a higher performance of  screening for SGA is achieved by sonographic fetal 
biometry during the third trimester; in these studies the DR varied from 54% to 75%, at screen 
positive rate (SPR) of 10-25%.5-11 A prospective study at 30-34 weeks’ gestation in 30,849 
singleton pregnancies, reported that screening by a combination of maternal characteristics and 
history with sonographic estimated fetal weight (EFW), predicted 80% of SGA neonates with birth 
weight <10th percentile delivering at <5 weeks of assessment, at 10% SPR; the respective DR for 
prediction of SGA neonates delivering at >5 weeks of assessment was 52%.12 A subsequent study 
of 9,472 singleton pregnancies at 30-34 weeks reported that the performance of screening by 
maternal factors and EFW was improved by the addition of uterine artery pulsatility index (UtA-
PI), mean arterial pressure (MAP) and serum placental growth factor (PlGF); the DR of SGA <10th 
percentile, at 10% SPR, was 89% for those delivering at <37 weeks' gestation but only 57% for 
those delivering at ≥ 37 weeks.13 Consequently, the performance of screening for SGA at 30-34 
weeks is acceptably high for those delivering preterm, but disappointingly low for those delivering 
at term. 
 
A randomized trial in 2,586 low-risk pregnancies reported that routine ultrasound examination at 
36 weeks' gestation is more effective than that at 32 weeks in detecting SGA neonates and related 
adverse perinatal and neonatal outcomes.14 A few studies examined the performance of screening 
for SGA at 35-37 weeks’ gestation by a combination of EFW and biomarkers. A study of 5,121 
pregnancies reported that in screening by maternal factors and EFW the DR of SGA <10th 
percentile delivering at ≥37 weeks was 66%, at 10% SPR, and this performance was not improved 
by the addition of UtA-PI and MAP.15 Similarly, a study of 946 pregnancies reported that screening 
by EFW predicted 59% of SGA <10th percentile, at 10% SPR, and the performance was not 
improved by the addition of UtA-PI and the cerebroplacental ratio (CPR).16 A study of 3,859 
pregnancies reported that in screening by maternal factors and EFW the DR of SGA <10th 
percentile delivering at ≥37 weeks was not improved by the addition of PLGF and soluble fms-
like tyrosine kinase-1 (sFLT).17 
                                                  
The objective of this study in 19,208 singleton pregnancies undergoing routine antenatal 
assessment at 35+0 - 36+6 weeks’ gestation is to investigate further the potential value of maternal 
factors, EFW and biomarkers of impaired placentation in the prediction of delivery of SGA 
neonates. 
 
METHODS 
 
Two datasets were used for this study. The first dataset comprised of 124,443 singleton 
pregnancies undergoing routine ultrasound examination at 11+0 - 13+6 weeks’ gestation at King’s 
College Hospital, London or Medway Maritime Hospital, Gillingham, UK between March 2006 and 
December 2016. This dataset was used to derive the patient-specific prior risk for delivery of a 
SGA neonate from maternal characteristics and medical history. The second dataset was derived 
from a prospective observational study in 19,209 women with singleton pregnancies attending for 
a routine hospital visit at 35+0 - 36+6 weeks’ gestation at King’s College Hospital, London or 
Medway Maritime Hospital, Gillingham, UK between March 2014 and September 2018. This visit 
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included recording of maternal demographic characteristics and medical history, ultrasound 
examination for fetal anatomy and measurement of fetal head circumference, abdominal 
circumference and femur length for calculation of EFW,18-20 transabdominal color Doppler 
ultrasound for measurement of the mean UtA-PI, UA-PI and MCA-PI,21,22 measurement of MAP 
by validated automated devices and a standardized protocol23 and measurement of serum 
concentration of PLGF and sFLT by an automated biochemical analyzer (Cobas e411 system, 
Roche Diagnostics, Penzberg, Germany, or BRAHMS KRYPTOR compact PLUS, Thermo Fisher 
Scientific, Hennigsdorf, Germany). Gestational age was determined by the measurement of fetal 
crown-rump length at 11-13 weeks or the fetal head circumference at 19-24 weeks.24,25  
 
The women gave written informed consent to participate in the study, which was approved by the 
NHS Research Ethics Committee. The inclusion criteria for this study were singleton pregnancies 
examined at 35+0 - 36+6 weeks’ gestation and delivering a non-malformed live birth or stillbirth. We 
excluded pregnancies with aneuploidies and major fetal abnormalities.  
 
Patient characteristics  
 
Patient characteristics recorded included maternal age, racial origin (White, Black, South Asian, 
East Asian and mixed), method of conception (natural, in vitro fertilization or use of ovulation 
induction drugs), cigarette smoking during pregnancy, medical history of chronic hypertension and 
diabetes mellitus, obstetric history including parity (parous or nulliparous if no previous 
pregnancies at > 24 weeks’ gestation), and previous pregnancy with SGA. The maternal weight 
and height were measured. 
 
Outcome measures 
 
Data on pregnancy outcome were collected from the hospital maternity records or the general 
medical practitioners of the women. The outcome measures of the study were birth of a neonate 
with birth weight <10th or <3rd percentile for gestational age at delivery.20  
 
Statistical analysis 
 
Data were expressed as median (interquartile range [IQR]) for continuous variables and n (%) for 
categorical variables. Mann-Whitney U-test and χ2-square test or Fisher’s exact test, were used 
for comparing outcome groups for continuous and categorical data, respectively. Significance was 
assumed at 5%. 
 
The a priori risk for SGA was calculated using multivariable logistic regression analysis with 
backward stepwise elimination to determine which of the factors among maternal characteristics 
and medical and obstetric history had a significant contribution in predicting SGA <10th. Prior to 
the regression analysis, the continuous variables, such as age, weight and height were centered 
by subtracting the arithmetic mean from each value to avoid effects of multicollinearity. Multiple 
categorical variables were dummy coded as binary variables to estimate the independent effect 
of each category. 
 
The observed measurements of EFW were expressed as Z-scores for gestational age.20 The 
measurements of UA-PI, MCA-PI, UtA-PI, MAP, PlGF and sFlt-1 were converted to multiple of 
the normal median (MoM).22,26 The dataset of 19,209 pregnancies was randomly divided into two 
separate datasets for development and validation of prediction models. Multivariable logistic 
regression analysis was then used in the training dataset to determine if the maternal factor-
derived logit (prior risk), EFW, UA-PI and MCA-PI, UtA-PI, MAP, PlGF and sFLT had a significant 
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contribution in predicting SGA <10th and SGA <3rd percentiles delivering within two weeks and at 
any stage after assessment. The performance of screening was determined by receiver operating 
characteristic (ROC) curves. The models developed from the multivariate analysis in the training  
dataset were then tested on the validation dataset to determine the performance of screening by 
analysis of ROC curves for various combination of biomarkers in addition to maternal factors and 
EFW.  
 
The statistical software package SPSS 24.0 (IBM SPSS Statistics for Windows, Version 24.0, 
Armonk, NY: IBM Corp; 2016) and Medcalc (Medcalc Software, Mariakerke, Belgium) were used 
for data analyses. 
 
RESULTS 
 
Patient characteristics 
 
The characteristics of the study population of 124,443 pregnancies examined at 11-13 weeks’ 
gestation for establishment of the prior risk and the 19,209 examined at 35+0 - 36+6 weeks, divided 
into training and validation datasets, are shown in Tables 1 and 2, respectively.  
 
In the 124,443 pregnancies examined at 11-13 weeks’ gestation the birth weight was <10th 
percentile in 15,641 (12.6%). The distribution of SGA <10th percentile that delivered at <32, 32-
36 and at >37 weeks’ gestation was 3.6% (n=559), 11.5% (n=1,803) and 84.9% (n=13,279), 
respectively.  
 
Prior risk for SGA 
 
The prior risk for SGA <10th is calculated from the following formula: odds/(1+odds), where 
odds=eY and Y is derived from multivariable logistic regression analysis. Regression coefficients 
and adjusted odds ratios of each of the maternal factors in the prediction algorithms are presented 
in Table 3. The likelihood of SGA increased with maternal age and decreased with maternal 
weight and height. The risk was higher in women of Black, South Asian, East Asian and mixed 
racial origins than in White women, in cigarette smokers, in those with chronic hypertension, 
diabetes mellitus type II and in parous women with prior history of SGA. The risk was lower in 
parous women without prior history of SGA and in those with diabetes mellitus type I.  
 
 
Biomarkers 
 
In the SGA <10th group, compared to those with birthweight ≥10th percentile, the median MoM 
values of PLGF (0.65 vs 1.04; p<0.001) and MCA-PI (0.96 vs. 0.99; p<0.001) were lower, whereas 
UtA-PI (1.06 vs 0.98; p<0.001), UA-PI (1.08 vs. 1.01; p<0.001) and sFLT (1.04 vs. 0.96; p<0.001) 
were higher. The deviations of biomarkers from normal were more pronounced in those with birth 
weight 3rd than the 10th percentile (p<0.001). In the SGA <10th group, the deviation in biomarker 
levels from normal decreased with increasing interval between assessment and delivery: EFW Z-
score r=0.087, p<0.001; UtA-PI: r=-0.110, p<0.001; MAP: r=-0.111, p<0.001; PlGF: r=0.203, 
p<0.001; sFlt-1: r=-0.216, p<0.001; UA-PI: r=-0.044, p<0.001; MCA-PI: r=0.082, p<0.001. There 
was no significant difference in the median biomarker MoM values between the training and 
validation datasets in either the SGA group or in those with birthweight ≥10th percentile (Table 2). 
 
Prediction of SGA  
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In the training dataset multivariable logistic regression analysis demonstrated that in the prediction 
of SGA <10th there were significant contributions from maternal factors, EFW Z-score, UtA-PI 
MoM, MCA-PI MoM and PlGF MoM (Table 4).  
 
The performance of predicting birth of SGA neonates at any stage after assessment at 35-37 
weeks by maternal factors, EFW and biomarkers is reported in Table 5. The AUROC curve and 
DR at 10% SPR in the validation dataset were consistent with those in the training dataset. The 
DRs at different SPRs for SGA <10th delivering within two weeks and at any time from assessment 
in screening by maternal factors, maternal factors and EFW Z-score and combined screening by 
maternal factors, EFW Z-score and biomarkers in the validation dataset are shown in Figure 1.  
 
In the validation dataset, the DR of SGA <10th delivering at any stage after assessment, at 10% 
SPR, was 32% in screening by maternal factors, 66% by maternal factors and EFW Z-score and 
69% by maternal factors, EFW Z-score and MoM values of UtA-PI, McCA-PI and PLGF; the 
respective values for SGA <3rd were 37%, 76% and 79% (Table 6). The DR of SGA <10th delivering 
within two weeks of assessment, at 10% SPR, was 31% (95% CI 25, 37; AUROC 0.718, 95% CI 
0.69., 0.744) in screening by maternal factors, 75% (95% CI 69, 81; AUROC 0.931, 95% CI 0.914, 
0.945) by maternal factors and EFW Z-score and 80% (95% CI 74, 86; AUROC 0.933, 95% CI 
0.917, 0.949) by maternal factors, EFW Z-score and MoM values of UtA-PI, MCA-PI and PLGF; 
the respective values for SGA <3rd were 33% (95% CI 25, 42; AUROC 0.726, 95% CI 0.699, 
0.652), 85% (95% CI 77, 91; AUROC 0.945, 95% CI 0.930, 0.958) and 83% (95% CI 77, 90; 
AUROC 0.945, 95% CI 0.930, 0.958).  
 
The SPRs necessary to achieve prediction of 85%, 90% and 95% of SGA neonates delivering 
within two weeks and at any stage from assessment are shown in Table 6. If the desired DR of 
SGA <10th delivering within two weeks of assessment was 90%, the necessary SPR would be 
67% in screening by maternal factors, 23% by maternal factors and EFW Z-score and 21% by 
the combined test; the respective values for SGA <3rd were 63%, 18% and 15%. 
 
DISCUSSION 
 
Main findings of the study 
 
The findings of this study demonstrate that the risk of delivering SGA neonates increases with 
maternal age, decreases with maternal weight and height, it is higher in women of Black, South 
Asian, East Asian and mixed racial origins than in White women, in cigarette smokers, in those 
with chronic hypertension, diabetes mellitus type II and in parous women with prior history of SGA. 
The risk is lower in parous women without prior history of SGA and in those with diabetes mellitus 
type I. The distribution of SGA <10th percentile that delivered at <32, 32-36 and at >37 weeks’ 
gestation was 3.6%, 11.5% and 84.9%, respectively; therefore, the vast majority of SGA neonates 
are born at term.  
 
In pregnancies that deliver SGA neonates EFW, PLGF and MCA-PI at 35+0 - 36+6 weeks’ gestation 
are reduced, whereas UtA-PI, UA-PI and sFLT are increased. The deviations of biomarkers from 
normal are more pronounced in those with severe disease reflected at lower birth weight (3rd vs. 
10th percentile) and delivery within two weeks rather than at any stage from assessment. 
Multivariable regression analysis demonstrated that significant independent conribution in the 
prediction of SGA was provided by maternal factors, EFW Z-score and MoM values of UtA-PI, 
MCA-PI and PlGF. Screening by maternal factors and EFW predicted 75% and 85% of SGA 
neonates with birth weight <10th and <3rd percentiles delivering within two weeks of assessment, 
at SPR of 10%; the respective values for SGA delivering at any stage after assessment were 66% 
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and 76%. Addition of other biomarkers had a marginal improvement in predictive performance of 
SGA neonates. If the desired DR of SGA <10th delivering within two weeks of assessment was 
90%, the necessary SPR would be 67% in screening by maternal factors, 23% by maternal factors 
and EFW and 21% by a combination of maternal factors, EFW and biomarkers of impaired 
placentation; the respective values for prediction of SGA neonates delivering at any stage after 
assessment were 66%, 32% and 30%. 
 
Strengths and limitations of the study 
 
The strengths of this third-trimester screening study for SGA are first, examination of a large 
population of pregnant women attending for routine assessment of fetal growth and wellbeing at 
35-37 weeks’ gestation and second, use of Bayes theorem to combine the prior risk from maternal 
characteristics and medical history with fetal biometry and biomarkers of impaired placentation to 
estimate patient-specific risks and the performance of screening for SGA of different severities 
delivering at selected intervals from the time of assessment, and third, using different datasets for 
training and validation of the prediction models.  
 
A limitation of the study is that the results of fetal biometry at the 35+0 - 36+6 weeks’ scan were 
made available to the obstetricians of the patients who would have taken specific actions of further 
monitoring for the cases of suspected SGA and consequently the performance of screening, 
particularly in those delivering within two weeks of assessment, would be positively biased.  
 
Comparison with findings from previous studies 
 
Our findings that prediction of SGA at term by a combination of maternal factors and EFW at 35-
37 weeks’ gestation is superior to that of screening at 30-34 weeks12 is consistent with the results 
of a previous study in 2,288 pregnancies undergoing ultrasound examination in both of these 
gestational windows10 and those of a randomized trial comparing the performance of ultrasound 
examination at 36 vs. 32 weeks' gestation.14 Similarly, the finding that the performance of 
screening for SGA at 35-37 weeks by maternal factors and biometry is not significantly improved 
by additional biomarkers is consistent with findings of previous smaller studies that examined the 
additional value of some of the biomarkers examined in this study.15-17 
 
Implications for clinical practice 
 
In the proposed new pyramid of pregnancy care,27 an integrated clinic at 11-13 weeks’ gestation, 
in which biophysical and biochemical markers are combined with maternal characteristics and 
medical history, aims to identify pregnancies at high-risk of preterm PE and / or SGA and through 
pharmacological intervention to reduce the prevalence of these complications.28-32  
 
The objective of subsequent visits, at around 20 and 32 or 36 weeks’ gestation, are to identify the 
high-risk group and through close monitoring of such pregnancies to minimize adverse perinatal 
events by determining the appropriate time and place for iatrogenic delivery. We have previously 
proposed that all women should be offered a third-trimester scan for assessment of fetal growth 
and wellbeing and that the timing of such scan, at 32 and / or 36 weeks, should be contingent on 
the results of assessment at around 20 weeks.33 Assessment at 20 weeks’ gestation would stratify 
the population into a high-risk group, which would comprise of <0.5% of all pregnancies and 
contain all cases of SGA delivering <32 weeks, a moderate-risk group comprising of about 16% 
of pregnancies and containing about 90% of cases of SGA that deliver at 32-36 weeks and a low-
risk group comprising of about 60% of pregnancies and containing about 90% of cases of SGA 
that deliver at ≥37 weeks. It was proposed that the high-risk group would require reassessment 
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at 26-28 weeks and then again at 32 and 36 weeks if not delivered, the moderate-risk group would 
be reassessed at 32 and 36 weeks and the low-risk group would be reassessed at 36 weeks.33 
Each assessment would then identify a very high-risk group in need of intensive monitoring, 
including fetal growth, biophysical profile, fetal heart rate patterns and fetal Doppler profile, to 
define the best plan for delivery. 
 
This study provides the necessary data for development of policies to achieve prenatal prediction 
of a desired percentage of SGA neonates. If the assessment at 36 weeks’ gestation includes a 
combination of maternal factors, EFW and biomarkers of impaired placentation it could potentially 
predict about 90% of SGA neonates delivering within two weeks of assessment at SPR of about 
20% and 90% of SGA neonates delivering at any stage after assessment at SPR of 30%. Although 
the additional value of PLGF, UtA-PI, UA-PI and MCA-PI is marginal in terms of prediction of SGA, 
PLGF is useful in the prediction of PE34 and UtA-PI, UA-PI and MCA-PI are important in the 
assessment of fetal oxygenation of SGA fetuses.35-40 The best management of the screen positive 
group with the objective of reducing perinatal death and handicap remains to be determined. 
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FIGURE LEGENDS 
 
Figure 1. Receiver operating characteristics curves of maternal factors (black line), maternal 
factors with estimated fetal weight (blue), maternal factors with estimated fetal weight and 
biomarkers (red) at 35+0 – 36+6 weeks’ gestation, in the prediction of small for gestational age 
neonates with birth weight below the 10th, delivering within two weeks (left) and at any time (right) 
from assessment 
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Table 1. Characteristics of the study population at 11+0 - 13+6 weeks’ gestation for estimation of 
prior risk. 
 
 
BW = birth weight; IQR = interquartile range; SGA = small for gestational age. 
  
Characteristic 
BW ≥10th percentile 
(n=108,802) 
SGA <10th percentile 
(n=15,641) 
P-value 
Maternal age in years, median (IQR) 31.2 (26.7-35.1) 30.3 (25.3-34.7) <0.001 
Maternal weight in Kg, median (IQR) 67.0 (60.0-78.0) 63.0 (56.0-73.0) <0.001 
Maternal height in cm, median (IQR) 165 (160-169) 162 (157-167) <0.001 
Gestation at screening in days, median (IQR) 89 (86-92) 89 (86-91) <0.001 
Racial origin    
   White, n (%) 83926 (77.1) 10028 (64.1) <0.001 
   Black, n (%) 16177 (14.9) 3522 (22.5) <0.001 
   South Asian, n (%) 4060 (3.7) 1237 (7.9) <0.001 
   East Asian, n (%) 2074 (1.9) 380 (2.4) <0.001 
   Mixed, n (%) 2565 (2.4) 474 (3.0) <0.001 
Cigarette smoker, n (%) 9820 (9.0) 2752 (17.6) <0.001 
Conception    
   Natural, n (%) 105245 (96.7) 15057 (96.3)  
   Ovulation drugs, n (%) 1285 (1.2) 207 (1.3) 0.126 
   In vitro fertilization, n (%) 2272 (2.1) 377 (2.4) 0.009 
Medical conditions    
   Chronic hypertension, n (%) 1205 (1.1) 374 (2.4) <0.001 
   Diabetes mellitus type 1, n (%) 479 (0.4) 41 (0.3) 0.001 
   Diabetes mellitus type 2, n (%) 467 (0.4) 88 (0.6) 0.011 
Past obstetric history    
   Nulliparous, n (%) 49537 (45.5) 8955 (57.3)  
   Parous with prior SGA, n (%) 10973 (10.1) 3039 (19.4) <0.001 
   Parous without prior SGA, n (%) 48292 (44.4) 3647 (23.3) <0.001 
Gestational age at delivery in weeks, median (IQR) 40.1 (39.0-40.9) 39.4 (38.1-40.5) <0.001 
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Table 2. Characteristics of the study population at 35+0 - 36+6 weeks’ gestation. 
 
Characteristic 
Training dataset Validation dataset 
BW ≥10th percentile 
(n=8592) 
SGA <10th percentile 
(n=1012) 
P-value 
BW ≥10th percentile 
(n=8593) 
SGA <10th percentile 
(n=1012) 
P-value 
Maternal age in years, median (IQR) 32.2 (28.1-35.7) 31.7 (27.2-35.4) <0.001 32.2 (28.1-35.7) 31.3 (26.6-35.2) <0.001 
Maternal weight in Kg, median (IQR) 79.8 (71.4-90.4) 74.0 (66.0-84.0) <0.001 79.5 (71.6-90.0) 73.0 (65.7-82.4) <0.001 
Maternal height in cm, median (IQR) 165 (161-170) 163 (159-167) <0.001 165 (161-170) 163 (158-167) <0.001 
Gestational age at screening in weeks, median (IQR) 36.1 (35.9-36.4) 36.1 (35.9-36.4) 0.654 36.1 (35.9-36.4) 36.1 (35.9-36.4) 0.096 
Racial origin       
   White, n (%) 6838 (79.6) 690 (68.2)  6846 (79.7) 671 (66.3)  
   Black, n (%) 976 (11.4) 180 (17.8) <0.001 1023 (11.9) 187 (18.5) <0.001 
   South Asian, n (%) 338 (3.9) 87 (8.6) <0.001 310 (3.6) 92 (9.1) <0.001 
   East Asian, n (%) 177 (2.1) 25 (2.5) 0.390 173 (2.0) 26 (2.6) 0.240 
   Mixed, n (%) 263 (3.1) 30 (3.0) 0.866 241 (2.8) 36 (3.6) 0.176 
Cigarette smoker, n (%) 527 (6.1) 125 (12.4) <0.001 535 (6.2) 135 (13.3) <0.001 
Conception       
   Natural, n (%) 8290 (96.5) 971 (95.9)  8303 (96.6) 970 (95.8)  
   Ovulation drugs, n (%) 49 (0.6) 6 (0.6) 0.928 48 (0.6) 7 (0.7) 0.359 
   In vitro fertilization, n (%) 302 (3.5) 41 (4.1) 0.384 290 (3.4) 42 (4.2) 0.202 
Medical conditions       
   Chronic hypertension, n (%) 85 (1.0) 16 (1.6) 0.081 94 (1.1) 14 (1.4) 0.409 
   Diabetes mellitus type I, n (%) 34 (0.4) 0 0.023 34 (0.4) 2 (0.2) 0.253 
   Diabetes mellitus type II, n (%) 63 (0.7) 4 (0.4) 0.152 57 (0.7) 3 (0.3) 0.110 
Past obstetric history       
   Nulliparous, n (%) 3915 (45.6) 589 (58.2)  3916 (45.6) 590 (58.3)  
   Parous without prior SGA, n (%) 4223 (49.2) 271 (26.8) <0.001 4221 (49.1) 270 (26.7) <0.001 
   Parous with prior SGA, n (%) 454 (5.3) 152 (15.0) <0.001 456 (5.3) 152 (15.0) <0.001 
Estimated fetal weight in percentile, median (IQR) 59.2 (35.9-79.4) 12.2 (3.9-27.6) <0.001 58.8 (35.4-79.2) 13.2 (3.9-27.5) <0.001 
Uterine artery PI MoM, median (IQR) 0.98 (0.84-1.16) 1.04 (0.86-1.28) <0.001 0.98 (0.84-1.15) 1.07 (0.89-1.29) <0.001 
Umbilical artery PI MoM, median (IQR) 1.01 (0.90-1.13) 1.08 (0.96-1.20) <0.001 1.01 (0.91-1.13) 1.08 (0.96-1.21) <0.001 
Middle cerebral artery PI MoM, median (IQR) 0.99 (0.89-1.09) 0.96 (0.86-1.08) <0.001 0.99 (0.89-1.11) 0.95 (0.86-1.08) <0.001 
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BW = birth weight; IQR = interquartile range; SGA = small for gestational age; MoM = multiple of the median; PI = pulsatility index; 
sFLT = soluble fms-like tyrosine kinase-1 
 
Comparisons between normals and SGA: Chi square test or Fisher exact test for categorical variables and Mann Whitney-U test or 
student t-test:*P<0.05 
Placental growth factor MoM, median (IQR)  1.03 (0.58-1.84) 0.63 (0.35-1.24) <0.001 1.04 (0.58-1.85) 0.65 (0.36-1.24) <0.001 
sFLT MoM, median (IQR) 0.96 (0.70-1.37) 1.03 (0.71-1.66) <0.001 0.96 (0.69-1.37) 1.05 (0.72-1.68) <0.001 
Gestational age at delivery in weeks, median (IQR) 40.0 (39.1-40.9) 39.4 (38.4-40.4) <0.001 40.0 (39.1-40.9) 39.4 (38.4-40.4) <0.001 
Birth weight in percentile, median (IQR) 55.7 (33.1-77.5) 4.5 (1.9-7.0) <0.001 55.5 (33.2-77.6) 4.6 (1.9-7.0) <0.001 
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Table 3. Fitted regression model with maternal characteristics and history for the prediction of 
small for gestational age neonates with birth weight below the 10th percentile. 
 
 
Characteristic 
Univariable Multivariable 
OR (95% CI) P value OR (95% CI) 
P 
value 
Maternal age - 30 (years) 0.98 (0.97, 0.98) <0.001 1.01 (1.00, 1.01) <0.001 
Maternal weight – 70 (Kg) 0.98 (0.97, 0.98) <0.001 0.98 (0.98, 0.99) <0.001 
Maternal height – 164 (cm) 0.94 (0.94, 0.95) <0.001 0.96 (0.96, 0.97) <0.001 
Racial origin     
   White (reference) 1.00    
   Black 1.82 (1.75, 1.90) <0.001 2.16 (2.07, 2.26) <0.001 
   South Asian 2.55 (2.39, 2.72) <0.001 2.00 (1.87, 2.15) <0.001 
   East Asian 1.53 (1.37, 1.71) <0.001 1.15 (1.02, 1.29) 0.021 
   Mixed 1.55 (1.40, 1.71) <0.001 1.45 (1.31, 1.61) <0.001 
Conception     
   Natural (Reference) 1.00  1.00  
Ovulation induction drugs 1.13 (0.97, 1.31) 0.116 1.22 (1.05, 1.43) 0.010 
   In vitro fertilization 1.16 (1.04, 1.30) 0.008 1.17 (1.05, 1.32) 0.007 
Cigarette smoker 2.15 (2.06, 2.25) <0.001 2.59 (2.47, 2.72) <0.001 
Medical disorders     
   Chronic hypertension 2.19 (1.95, 2.46) <0.001 2.39 (2.11, 2.72) <0.001 
Diabetes mellitus type I 0.60 (0.43, 0.82) 0.001 0.62 (0.45, 0.86) 0.004 
Diabetes mellitus type II 1.31 (1.04, 1.65) 0.020 1.35 (1.06, 1.71) 0.017 
Past obstetric history     
   Nulliparous (Reference) 1.00  1.00  
   Parous with no prior SGA, n (%) 0.42 (0.40, 0.44) <0.001 0.40 (0.39, 0.42) <0.001 
   Parous with prior SGA, n (%) 1.53 (1.46, 1.60) <0.001 1.23 (1.17, 1.29) <0.001 
 
OR = odds ratio; CI = confidence interval; SGA = small for gestational age 
 
Y=-2.05847 + (0.00664*Age) + (-0.01585*Weight) + (-0.04113*Height) + 
(0.77099*Black) + (0.69489*South Asian) + (0.13596*East Asian) + (0.36953*Mixed race) + 
(0.20161*Ovulation drugs) + (0.15918*IVF conception) + (0.95299*Smoking) + 
(0.87258*Chronic hypertension) + (-0.47573*Diabetes type I) + (0.29632*Diabetes type II) + 
(-0.90660*Parous no previous SGA) + (0.20848*Parous previous SGA) 
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Table 4. Fitted regression models with maternal characteristics and history (maternal factors), 
estimated fetal weight Z-score and biomarkers at 35+0 – 36+6 weeks’ gestation for the prediction 
of small for gestational age neonates with birth weight below the 10th percentile. 
 
 
 
SE = standard error; OR = odds ratio; CI = confidence interval; EFW = estimated fetal weight; 
MoM = multiple of the median; PI = pulsatility index.  
 
Independent variable Coefficient SE OR 95% CI P-value 
Intercept 0.85804 0.08038    
Maternal factors + EFW 3.11053 0.09374 22.43 (18.67, 26.96) <0.001 
Uterine artery PI MoM 0.72495 0.34741 2.07 (1.05, 4.08) <0.001 
Middle cerebral artery PI MoM -2.17359 0.61731 0.11 (0.03, 0.38) <0.001 
Placental growth factor MoM -1.39096 0.11557 0.25 (0.20, 0.31) <0.001 
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Table 5. Performance of prediction of small for gestational age neonates with birth weight <10th, 
and <3rd percentile delivering at any stage after screening at 35+0 – 36+6 weeks’ gestation. 
 
 
AUROC = area under the receiver operating characteristic curves; CI = confidence interval; EFW 
= estimated fetal weight; SGA = small for gestational age; DR = detection rate; SPR = screen 
positive rate; UtA-PI = uterine artery pulsatility index; UA-PI = umbilical artery pulsatility index; 
MCA-PI = middle cerebral artery pulsatility index.  
  
Screening test 
Training dataset Validation dataset 
AUROC curve 
(95% CI) 
DR at 10% SPR 
% (95% CI) 
AUROC curve 
(95% CI) 
DR at 10% SPR 
% (95% CI) 
SGA <10th percentile     
Maternal factors  0.709 (0.693-0.725) 30 (27, 33) 0.719 (0.710-0.728) 32 (30, 36) 
Maternal factors plus EFW Z-score 0.891 (0.885-0.897) 67 (64, 70) 0.890 (0.883-0.896) 66 (63, 69) 
   Mean arterial pressure 0.892 (0.886-0.898) 67 (64, 70) 0.891 (0.884-0.897) 66 (63, 69) 
   UtA-PI 0.892 (0.887-0.898) 67 (64, 70) 0.892 (0.886-0.899) 67 (64, 70) 
   UA-PI 0.893 (0.886-0.899) 68 (65, 71) 0.892 (0.885-0.898) 68 (65, 71) 
   MCA-PI 0.894 (0.887-0.898) 68 (65, 71) 0.891 (0.885-0.897) 66 (63, 69) 
   Placental growth factor 0.902 (0.896-0.908) 70 (67, 72) 0.897 (0.891-0.903) 69 (66, 72) 
   Soluble fms-like tyrosine kinase-1 0.895 (0.888-0.899) 68 (65, 71) 0.891 (0.884-0.897) 67 (64, 70) 
   UtA-PI + UA-PI + MCA-PI 0.895 (0.888-0.900) 68 (65, 71) 0.893 (0.887-0.899) 67 (64, 70) 
   UtA-PI + MCA-PI + PLGF 0.903 (0.897-0.909) 70 (67, 72) 0.898 (0.892-0.904) 69 (66, 72) 
SGA <3rd percentile     
Maternal factors  0.743 (0.719-0.768) 40 (34, 45) 0.738 (0.729-0.747) 37 (32, 42) 
Maternal factors plus EFW Z-score 0.931 (0.926-0.936) 77 (72, 81) 0.920 (0.915-0.926) 76 (71, 80) 
   Mean arterial pressure 0.931 (0.926-0.936) 79 (74, 83) 0.921 (0.916-0.927) 76 (71, 81) 
   UtA-PI 0.933 (0.927-0.937) 78 (74, 83) 0.922 (0.916-0.927) 76 (71, 80) 
   UA-PI 0.931 (0.926-0.936) 78 (74, 83) 0.923 (0.917-0.928) 76 (71, 80) 
   MCA-PI 0.932 (0.927-0.937) 78 (74, 82) 0.922 (0.916-0.927) 76 (71, 80) 
   Placental growth factor 0.939 (0.934-0.943) 82 (77, 86) 0.925 (0.920-0.931) 77 (73, 82) 
   Soluble fms-like tyrosine kinase-1 0.936 (0.931-0.941) 80 (75, 84) 0.921 (0.916-0.927) 76 (72, 81) 
   UtA-PI + UA-PI + MCA-PI 0.932 (0.927-0.937) 80 (75, 84) 0.924 (0.918-0.929) 77 (72, 81) 
   UtA-PI + MCA-PI + PLGF 0.940 (0.735-0.745) 82 (78, 86) 0.929 (0.923-0.934) 79 (74, 83) 
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Table 6. Screen positive rate necessary to achieve prediction of 85%, 90% and 95% of small for 
gestational age neonates delivering within two weeks and at any stage after assessment at 35+0 
– 36+6 weeks’ gestation. 
 
 
SPR = screen positive rate; CI = confidence interval; SGA = small for gestational age; EFW = 
estimated fetal weight; DR = detection rate; UtA-PI = uterine artery pulsatility index; MCA-PI = 
middle cerebral artery pulsatility index; PLGF = placental growth factor.  
 
 
 
Screening test 
SPR for 85% DR 
% (95% CI) 
SPR for 90% DR% 
(95% CI) 
SPR for 95% 
DR% (95% CI) 
SGA within 2 weeks    
SGA <10th percentile    
  Maternal factors  60 (57, 63) 67 (64, 70) 83 (80, 85) 
  Maternal factors + EFW Z-score 16 (13, 18) 23 (20, 26) 31 (28, 34) 
  + UtA-PI + MCA-PI + PLGF 13 (11, 16) 21 (19, 24) 29 (26, 33) 
SGA <3rd percentile    
  Maternal factors  57 (53, 60) 63 (60, 66) 70 (67, 73) 
  Maternal factors + EFW Z-score 12 (10, 14) 18 (16, 21) 27 (24, 30) 
  + UtA-PI + MCA-PI + PLGF 11 (9, 13) 15 (13, 18) 21 (19, 24) 
SGA at any stage    
SGA <10th percentile 59 (58, 60) 66 (65, 67) 84 (83, 85) 
  Maternal factors  24 (23, 25) 32 (31, 33) 43 (42, 44) 
  Maternal factors + EFW Z-score 23 (22, 24) 30 (29, 31) 40 (39, 41) 
  + UtA-PI + MCA-PI + PLGF    
SGA <3rd percentile 60 (59, 61) 68 (67, 69) 75 (74, 76) 
  Maternal factors  17 (16, 18) 23 (22, 24) 31 (30, 32) 
  Maternal factors + EFW Z-score 15 (14, 16) 20 (19, 21) 28 (27, 29) 
  + UtA-PI + MCA-PI + PLGF 59 (58, 60) 66 (65, 67) 
84 (83, 85) 
 
